SPRO — Spero Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $78.68m
- $2.35m
- $103.78m
- 37
- 98
- 88
- 87
Annual cashflow statement for Spero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60.9 | -78.3 | -89.8 | -46.4 | 22.8 |
| Depreciation | |||||
| Non-Cash Items | 3.38 | 5.11 | 11.9 | 15.7 | 14.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.78 | -13.5 | 12.9 | 22.1 | -70.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -50 | -85.9 | -64.3 | -7.73 | -33 |
| Capital Expenditures | -0.314 | -0.157 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 29.8 | 10.6 | 7.67 | 33.8 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 29.5 | 10.5 | 7.67 | 33.8 | 0 |
| Financing Cash Flow Items | -0.158 | -0.953 | 47.2 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.1 | 131 | 84 | -29.6 | 0.221 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.35 | 55.5 | 27.4 | -3.48 | -32.8 |